Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02906670 · ClinicalTrials.gov registry record · Phase 1
Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies
A Phase 1 study, sponsored by Symphogen A/S.
- Terminated
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02906670: Clinical Trial Phase 1 study, sponsored by Symphogen A/S.
NCT02906670 is a Phase 1 study that was terminated before completion, run by Symphogen A/S. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02906670, a Phase 1 study, was terminated before completion, sponsored by Symphogen A/S.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is the first study to test Sym013 (Pan-HER) in humans. The primary purpose of this study is to see if Sym013 is safe and effective for patients with advanced epithelial malignancies without available therapeutic options.
Primary Outcome
Assess the occurrence of dose-limiting toxicities (DLTs) during Cycle 1 of Sym013 administration.
Interventions
- DRUG Sym013
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-11-01 |
| Est. Completion | 2019-06 |
| Phase | Phase 1 |
Why NCT02906670 stopped before completion
NCT02906670 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 1 intervention - of which Sym013 is the first listed.
NCT02906670 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02906670 about?
NCT02906670 is a clinical study titled "Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies". This is the first study to test Sym013 (Pan-HER) in humans. The primary purpose of this study is to see if Sym013 is safe and effective for patients with advanced epithelial malignancies without available therapeutic options.
What is the current status of trial NCT02906670?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2016-11-01. Estimated completion is 2019-06.
What interventions are being tested in trial NCT02906670?
The interventions under investigation include: Sym013 (DRUG).
Who is sponsoring clinical trial NCT02906670?
This trial is sponsored by Symphogen A/S, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02906670's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI